title: Pediatric uveitis: new and future treatments.
abstract: OBJECTIVE
  Pediatric uveitis is relatively uncommon, accounting for only 5-10% of all patients with uveitis. However, owing to high prevalence of complications and devastating outcomes, its lifetime burden can be significant.
  
  
  RESULTS
  Immunomodulatory therapy has been associated with better outcomes in noninfectious pediatric uveitis. However, effective treatments are limited by medication-related complications, including multiorgan toxicities and systemic side effects.
  
  
  CONCLUSIONS
  We review the current therapies available to treat pediatric uveitis, discuss novel and future therapies, and provide clinical recommendations utilizing these new agents. The consideration for treatment regimens in noninfectious pediatric uveitis is multifactorial. Understanding past, present, and future technology will aid in treatment of a complex and refractory disease.
authors.affiliation: National Eye Institute/National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: Preema J
authors.initials: PJ
authors.lastname: Mehta
authors.forename: Janet L
authors.initials: JL
authors.lastname: Alexander
authors.forename: H Nida
authors.initials: HN
authors.lastname: Sen
mesh_terms: D000293:Adolescent; D001691:Biological Therapy; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D014605:Uveitis / Q000209:etiology / Q000628:therapy*
chemical_list: D007166:Immunosuppressive Agents